Orforglipron
Oral non-peptide GLP-1R agonist for convenient diabetes and obesity management. Small molecule alternative to injectable peptides with comparable efficacy and improved patient compliance.
Orforglipron (code name LY3502970 / OWL833) is a novel, orally bioavailable, non-peptide small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. Unlike existing GLP-1 receptor agonists such as liraglutide and semaglutide, which are peptide-based injectables, orforglipron represents a paradigm shift in incretin therapy as a fully synthetic small molecule that can be administered orally without absorption enhancers or dietary restrictions.
| Parameter | Specification |
| CAS | 2212020-52-3 |
| Molecular Formula | C₄₈H₄₈F₂N₁₀O₅ |
| Molecular Weight | 882.96 g/mol |
| Category | GLP-1/Metabolic |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Type 2 diabetes, obesity, oral GLP-1 therapy research |
| CAS | 2212020-52-3 |
|---|---|
| Applications |
Related products
-
Glucagon HCl
CAS: 16941-32-5Applications: Diabetic Emergency, Glycogenolysis, Hypoglycemia Rescue -
Retatrutide
CAS: 2381089-83-2Applications: Refractory diabetes, Severe obesity, Triple agonist, weight management -
Exenatide Acetate
CAS: 141732-76-5Applications: GLP-1, obesity management, Type 2 diabetes -
Liraglutide
CAS: 204656-20-2Applications: cardiovascular risk reduction, GLP-1, obesity management